Kim Brazzell

Kim Brazzell is the Head of R&D and Chief Medical Officer at Kala Pharmaceuticals. Dr. Brazzell brings more than 25 years of experience in the ophthalmic pharmaceutical industry to Kala. Previously, he held several executive positions at Inspire Pharmaceuticals, including Executive Vice President, Medical and Scientific Affairs, Executive Vice President and Head, Ophthalmology Business and Senior Vice President of Ophthalmic Research and Development. Prior to joining Inspire, he served as Global Head of Clinical R&D and Senior Vice President, U.S. R&D, of Novartis Ophthalmics.

He has extensive experience in the discovery and development of multiple successful ophthalmic products including Visudyne®, Zaditor®, RESCULA® and Betoptic S®. In addition to managing the global clinical R&D group for Novartis Ophthalmics, Dr. Brazzell built and managed the U.S.-based R&D group for Ciba Vision Ophthalmics, while serving as their Vice President, R&D, and served as Associate Director, R&D, at Alcon Laboratories, Inc. Dr. Brazzell received a B.S. in pharmacy and a Ph.D. in pharmaceutical sciences from the University of Kentucky.

Kim Brazzell is the Head of R&D and Chief Medical Officer at Kala Pharmaceuticals, based in United States, North America. With a background in Biotechnology, Kim Brazzell has a rich history of leadership and innovation.Kim Brazzell studied Ph.D Pharmaceutical Sciences at University of Kentucky. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.